Summit Therapeutics stockSMMT
Summit Therapeutics trades at $14.19, 51.5% below its 52-week high (Apr 21, 2026). The price is below its 50- and 200-day averages, a downtrend. −18.9% year to date, −21.5% over 12 months (S&P 500 over the same period: +8.8%). Next earnings report: Mar 18, 2027.
- Market pulseSummit Therapeutics announces its third-quarter and nine-month 2026 financial results and provides an update on operational progress.
- Market pulseSummit Therapeutics reports Q3 2026 results with non-GAAP EPS -$0.20 (+35% YoY), beating EPS estimates
- Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
Ratings, candles, signals and the screener for SMMT — after you log in
Open the terminalFrequently asked questions about Summit Therapeutics
What is the Summit Therapeutics stock price?
At the close on Nov 5, 2026: $14.19 (−12.24% on the day). 52-week high: $29.23 on Apr 21, 2026. During the session the price is updated with a 15-minute delay, after the close with the day's final figures.
When does Summit Therapeutics report earnings?
The next quarterly report is on Mar 18, 2027. Last quarter, earnings per share changed +16% year over year, revenue 0%.
Does Summit Therapeutics pay dividends?
No, Summit Therapeutics does not pay dividends.
Where does Summit Therapeutics trade and how to buy it?
Ticker SMMT, exchange Nasdaq. You can buy it through a broker with access to US exchanges.
Should I buy Summit Therapeutics now?
We do not give buy or sell advice. Ratings, the detailed chart and signals for SMMT are in the terminal after you log in.